AlveoGene Analysis: $3M Raised
What is AlveoGene?
AlveoGene focuses on transforming outcomes for rare respiratory diseases through inhaled gene therapy. Their technology aims to address unmet medical needs in this specialized field. The company is dedicated to advancing therapeutic options for patients suffering from these conditions.
Location
46 Woodstock Rd, Oxford OX2 6HT, United Kingdom
Employees
1-10
Founded
2022
Funding Status
Seed
Product Features & Capabilities
- Inhaled gene therapy solutions for rare respiratory diseases
Use Cases
Targeting specific rare respiratory diseases with gene therapy; Developing inhalation delivery systems for therapeutic agents; Conducting clinical trials for efficacy and safety; Collaborating with research institutions for innovative solutions; Engaging with healthcare providers for patient access
See something that needs updating? Suggest edits to this profile.